Achieve Secures Adare Pharma Partnership and FDA Sets June 20 PDUFA Date
Achieve ended 2025 with $36.4 million in cash and marketable securities and recorded a net loss of $54.7 million on operating expenses of $54.9 million. The company secured a U.S. manufacturing partnership with Adare Pharma, received FDA acceptance of its cytisinicline NDA with a June 20, 2026 PDUFA date, and plans a commercial launch in H1 2027.
1. Financial Results
Achieve reported cash, cash equivalents, and marketable securities of $36.4 million as of December 31, 2025. Operating expenses totaled $54.9 million for the full year, resulting in a net loss of $54.7 million, reflecting continued investment in its cytisinicline development program.
2. Manufacturing Partnership with Adare Pharma
The company selected U.S.-based Adare Pharma Solutions to manufacture cytisinicline drug product for potential commercial launch. This partnership aims to lower importation risks and tariffs, provide supply chain redundancy, and reduce production costs through a technology transfer already under way.
3. Regulatory Milestones and Clinical Data
FDA accepted the cytisinicline NDA for smoking cessation with a PDUFA action date of June 20, 2026. Achieve completed a 334-participant long-term exposure trial, secured a National Priority Voucher for vaping cessation, and published ORCA-3 and Thorax data demonstrating significant abstinence and tolerability benefits.
4. Commercial and Supply Chain Preparations
Preparations for U.S. commercial readiness include third-party logistics and specialty pharmacy partner selection, plus an Omnicom-led data-driven commercial model. The company anticipates launching cytisinicline in the first half of 2027, backed by published safety and efficacy evidence.